Observing Immune Responses to Monkeypox Vaccine in Adults With and Without HIV at High Risk

What this Trial Is About

This observational study aims to understand how the immune system responds after vaccination against monkeypox in both HIV positive and HIV negative adults who are at high risk of infection. The study focuses on people involved in the current monkeypox outbreak and seeks to learn about the bodys antibody and cellular responses after receiving the vaccine. Given the recent outbreak and the specific concerns for people living with HIV, this research is important to provide insight into vaccine responses in these groups. Participants include adults aged 18 and older who receive the monkeypox vaccine as a preventive measure. The vaccine is given according to current health recommendations, including a single intradermal dose due to limited vaccine availability. The study observes two groups HIV positive individuals and HIV negative individuals, both vaccinated for pre-exposure protection. The study will take place during the vaccination campaign and includes follow-up visits to monitor immune responses over time. During the study, participants will have blood samples taken at different times between 29 and 180 days after vaccination to measure antibody levels and immune activity. Researchers will assess the presence and strength of specific antibodies against the monkeypox virus and compare responses between HIV positive and negative participants. The study tracks these immune responses to better understand vaccine effects and safety, with follow-up lasting several months after vaccination.

Characterization of Vaccine-induced Responses Against Monkeypox (MoVIHvax) An Observational Prospective Cohort Study